 |
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/227843
The Pharmaceutical Market: Russia
|
Description: |
THE PHARMACEUTICAL MARKET: RUSSIA - REVIEW
Russia accounts for two-fifths of the total Central & Eastern European pharmaceutical market, due to its large GDP and population of 142 million; however, in per capita terms, Russia is also one of the smallest markets, comparing to Romania. The Russian pharmaceutical market is predicted to expand at a relatively high CAGR in US dollar terms over the next few years and will continue to be driven by import growth; a heavy reliance on imports has resulted from the lack of locally-manufactured innovative pharmaceuticals. Over the last few years, import growth has been boosted by the federal drug supply system (DLO). Around 80% of DLO funds are spent on imported pharmaceuticals.
The government is currently implementing the Pharma 2020 Strategy, which aims to encourage growth in the local pharmaceutical industry for the period up to 2020. Under the plan, the government will help local producers to cover the costs of the R&D that is required to boost production of innovative pharmaceuticals. It also hopes to create new companies that will be able to attract investment, create new jobs and produce competitive, safe, good quality, affordable products that fulfil the requirements of patients and the healthcare system. If the objectives of the plan are realised, by 2020, the local industry will be responsible for 50% of drugs in circulation, 80% of which will be innovative. The Strategy will require a lot of investment which will be sourced mainly from the federal budget, but the government is also trying to encourage international pharmaceutical companies to invest. So far, companies such as AstraZeneca, Novo Nordisk and Nycomed have made plans to invest in Russia.
The presence of foreign manufacturers is increasing in Russia. A number of agreements have been made in 2011 between domestic and foreign companies which will benefit the Russian pharmaceutical market. These include a joint venture between India's Aurobindo Pharma and Russia's OJSC Diod; a licensing agreement between Norgine and Nycomed that gives the latter exclusive rights to commercialise MoviPrep in Russia; investment by Rusnano, Russia’s government investment company, in Cleveland BioLabs' new subsidiary, Panacela Labs, which will develop a portfolio of new preclinical drug candidates in Russia; Pfizer and ChemRar High Technology Centre signing a memorandum of understanding to explore a collaboration focused on the research, development and commercialisation of innovative drugs in Russia; and the launching of Pro Bono Bio as a new international pharmaceutical company as a result of a three-year Anglo/Russian project.
ENHANCED STRATEGIC INTELLIGENCE
These highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
- Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
- Specialised intelligence on OTCs, generics, biologics and biosimilars.
- Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
- A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
- The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included. |
|
Contents: |
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
EXECUTIVE SUMMARY
Including Espicom's at a glance strategic analysis and key data projections
MACROENVIRONMENT
Political, economic, legal and demographic analysis
EPIDEMIOLOGY
Disease burden and prevalence
HEALTHCARE
Organisation, expenditure, infrastructure, services and workforce
REGULATORY AFFAIRS
Regulatory developments and marketing registration/authorisation
PRICING & REIMBURSEMENT
DISTRIBUTION CHANNELS
MARKET ANALYSIS
Projections, product development, manufacturing and trade
COMPETITION
Trade associations, trade fairs, company intelligence and competitive strategies
OTC PHARMACEUTICALS
GENERIC PHARMACEUTICALS
BIOLOGICS & BIOSIMILARS
OPPORTUNITIES & CHALLENGES
Espicom's unique strategic analysis
DIRECTORY
METHODOLOGY & SOURCES |
|
Companies Mentioned |
- Akrikhin
- Bryntsalov A
- JSC Farmacon
- KRKA
- Makiz
- Nizhpharm
- Otechestvennye Lekarstva (Erka Farm)
- Pharmstandard
- Veropharm
- Yugrafarm |
|
Ordering: |
Order Online - visit http://www.researchandmarkets.com/reports/227843
Order by Fax - using the order form below
Order By Post - print the order form below and send to
|
|
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
 |
Page 1 of 2
Printed 13/02/2012 08:21:32 |
|
Fax Order Form
To place an order via fax simply print this form, fill in the information below and
fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net
Order information
Please verify that the product information is correct and select the format you require.
|
|
|
|
Product Name: |
The Pharmaceutical Market: Russia
|
|
Web Address: |
http://www.researchandmarkets.com/reports/227843
|
|
Office Code: |
|
OC8IHINLSNNSS
|
Report formats
Please enter the quantity of the report format you require.
|
|
Format
|
Quantity
|
Price
|
|
Electronic (Online Access)
- Enterprisewide
|
|
€5,050.00
|
|
Electronic (PDF)
- Enterprisewide
|
|
€5,050.00
|
|
Electronic (Online Access)
- Single User
|
|
€775.00
|
|
Hard Copy
|
|
€775.00 + EUR€ 50.00 Shipping/Handling *
|
|
Electronic (PDF)
- Single User
|
|
€775.00
|
* Shipping/Handling is only charged once per order.
Contact information
Please enter all the information below in BLOCK CAPITALS.
|
|
|
First Name: |
Last Name: |
|
Email Address: |
|
|
Job Title: |
|
|
Organisation: |
|
|
Address: |
|
|
City: |
|
|
Postal/Zip Code: |
|
|
Country: |
|
|
Phone Number: |
|
|
Fax Number: |
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
|
|
Page 2 of 2
Printed 13/02/2012 08:21:32
|
|
Payment information
Please indicate the payment method you would like to use by selecting the appropriate
box.
|
|
|
|
|
American Express
|
|
|
Diners Club
|
|
|
Master Card
|
|
|
Visa
|
|
|
|
|
|
|
Cardholder's Name: |
|
|
|
|
Cardholder's Signature: |
|
|
|
|
Expiry Date: |
/ |
|
|
|
Card Number: |
|
|
|
|
CVV Security Code: |
|
|
|
|
Issue Date: |
/ (Diners
Club only)
|
|
|
|
|
|
|
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
|
|
|
|
Please transfer funds to:
|
|
|
Account number: |
83313083 |
|
Sort code: |
98-53-30 |
|
Swift code: |
ULSBIE2D |
|
IBAN number: |
IE78ULSB98533083313083 |
|
Bank Address: |
Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland. |
|
|
|
If you have a Marketing Code please enter it below:
|
|
|
Marketing Code: |
|
|
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
|
|
|
|
|
|
